Q-omics provides the consensus-scored KCTD9P4 profile across patient tissues and cancer cell-line models. KCTD9P4 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KCTD9P4 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, KCTD9P4 RNA expression shows 13,236 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where KCTD9P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCTD9P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCTD9P4 survival associations across molecular data types. KCTD9P4 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCTD9P4 RNA expression–survival associations across cancer types. High KCTD9P4 expression shows unfavorable associations in KIRC, THCA and LGG, but favorable associations in HNSC, SKCM and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KCTD9P4 RNA expression.
This table summarizes KCTD9P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KCTD9P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCTD9P4 shows lower tumor expression in KIRC, THCA, BLCA, LIHC and LUAD and higher tumor expression in KIRP. The KIRC box plot shows higher KCTD9P4 RNA expression in normal versus tumor tissue (log2 FC = −0.165, t-test p < 0.001).
This table shows molecular features associated with KCTD9P4 in patient tissues and cancer cell lines. In patient samples, KCTD9P4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
